DOI: https://doi.org/10.22263/2312-4156.2020.6.31
Palhuyeva H.Y., Litvyakov A.M.1, Lagutchev V.V.
Rheumatoid arthritis and atherosclerosis: common features in immunopathogenesis. Literature review
Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
Vestnik VGMU. 2020;19(6):31-40.
Abstract.
The results of numerous studies demonstrate the relationship between rheumatoid arthritis (RA) and atherosclerosis.
The fact of early occurrence and rapid progression of cardiovascular diseases in patients with RA is well known, but there is still no exact explanation for this phenomenon. It is clearly known that such accelerated course of the atherosclerotic process cannot be explained from the position of traditional cardiovascular risk factors. Rheumatoid arthritis can serve as a model for studying accelerated atherogenesis.
A number of similar immunological processes take place in the pathogenesis of atherosclerosis and RA. In these diseases, CD4+ T-lymphocytic reaction prevails. A genetic defect common to RA and atherosclerosis in the regulation of the MHC class II antigen-presenting mechanism is described. Heat shock proteins are considered as possible antigens that cause T-cell activation, in particular, a typical representative of this group of proteins – HSP 60.
Neoangiogenesis is an important phenomenon in RA that leads to the articular cartilage destruction. In atherosclerosis, neoangiogenesis is important in the invasive growth of atherosclerotic plaque. Processes of tissue destruction mediated by matrix metalloproteases result in destabilization of atherosclerotic plaque in atherosclerosis and destruction of joint tissues in RA.
Effective RA therapy can be accompanied by the improvement in the vascular bed condition.
Key words: atherosclerosis, rheumatoid arthritis, inflammation, cytokines, neoangiogenesis, heat shock proteins.
References
1. Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first time acute myocardial infarction. Am J Cardiol. 2004 Jan;93(2):198-200. doi: http://dx.doi.org/10.1016/j.amjcard.2003.09.037
2. Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 year. Arthritis Rheum. 2005 Feb;52(2):412-20. doi: http://dx.doi.org/10.1002/art.20855
3. Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2010 Feb;49(2):295-307. doi: http://dx.doi.org/10.1093/rheumatology/kep366
4. Robertson A-KL, Hansson GK. T cells in atherogenesis. For better or for worse. Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2421-32. doi: http://dx.doi.org/10.1161/01.ATV.0000245830.29764.84
5. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001 Mar;344(12):907-16. doi: http://dx.doi.org/10.1056/NEJM200103223441207
6. Swanberg M, Lidman O, Padyukov L, Eriksson P, Akesson E, Jagodic M, et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet. 2005 May;37(5):486-94. doi: http://dx.doi.org/10.1038/ng1544
7. Gaston JSH. Cytokines in arthritis – the ‘big numbers’ move centre stage. Rheumatology (Oxford). 2008 Jan;47(1):8-12. doi: http://dx.doi.org/10.1093/rheumatology/kem203
8. Umemura M, Kawabe T, Shudo K, Kidoya H, Fukui M, Asano M, et al. Involvement of IL-17 in Fas ligand-induced inflammation. Int Immunol. 2004;16(8):1099-108. doi: http://dx.doi.org/10.1093/intimm/dxh111
9. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999 May;103(9):1345-52. doi: http://dx.doi.org/10.1172/JCI5703
10. Schaper W. Collateral circulation: past and present. Basic Res Cardiol. 2009 Jan;104(1):5-21. doi: http://dx.doi.org/10.1007/s00395-008-0760-x
11. Frostegård J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999 Jul;145(1):33-43. doi: http://dx.doi.org/10.1016/s0021-9150(99)00011-8
12. Kishikawa H, Shimokama T, Watanabe T. Localization of T lymphocytes and macrophages expressing IL-1, IL-2 receptor, IL-6 and TNF in human aortic intima. Role of cell-mediated immunity in human atherogenesis. Virchows Arch A Eur J Pathol. 1993;423:433-42. doi: http://dx.doi.org/10.1007/BF01606532
13. van der Wal AC, Piek JJ, de Boer OJ, Koch KT, Teeling P, van der Loos CM, et al. Recent activation of the plaque immune response in coronary lesions underlying acute coronary syndromes. Heart. 1998 Jul;80(1):14-8. doi: http://dx.doi.org/10.1136/hrt.80.1.14
14. Liuzzo G, Kopecky S, Frye RL, O'Fallon WM, Maseri A, Goronzy JJ, et al. Perturbation of the T cell repertoire in patients with unstable angina. Circulation. 1999 Nov;100(21):2135-9. doi: http://dx.doi.org/10.1161/01.cir.100.21.2135
15. Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation. 2000 Jun;101(25):2883-8. doi: http://dx.doi.org/10.1161/01.cir.101.25.2883
16. Martens PB, Goronzy JJ, Schaid D, Weyand CM. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum. 1997 Jun;40(6):1106-14. doi: http://dx.doi.org/10.1002/art.1780400615
17. Gerli R, Schillaci G, Giordano A, Bartoloni Bocci E, Bistoni O, Vaudo G, et al. CD4+ CD28 – T Lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation. 2004 Jun 8;109(22):2744-8. doi: http://dx.doi.org/10.1161/01.CIR.0000131450.66017.B3
18. Maguire M, Coates AR, Henderson B. Chaperonin 60 unfolds its secrets of cellular communication. Cell Stress Chaperones. 2002 Oct;7(4):317-29. doi: http://dx.doi.org/10.1379/1466-1268(2002)007<0317:cuisoc>2.0.co;2
19. Gupta S, Knowlton AA. HSP60 trafficking in adult cardiac myocytes: role of the exosomal pathway. Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H3052-6. doi: http://dx.doi.org/10.1152/ajpheart.01355.2006
20. Lewthwaite J, Owen N, Coates A, Henderson B, Steptoe A. Circulating human heat shock protein 60 in the plasma of British civil servants: relationship to physiological and psychosocial stress. Circulation. 2002 Jul;106(2):196-201. doi: http://dx.doi.org/10.1161/01.cir.0000021121.26290.2c
21. Pockley AG, Bulmer J, Hanks BM, Wright BH. Identification of human heat shock protein 60 (Hsp60) and anti-Hsp60 antibodies in the peripheral circulation of normal individuals. Cell Stress Chaperones. 1999 Mar;4(1):29-35. doi: http://dx.doi.org/10.1054/csac.1998.0121
22. Xu Q, Schett G, Perschinka H, Mayr M, Egger G, Oberhollenzer F, et al. Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation. 2000 Jul;102(1):14-20. doi: http://dx.doi.org/10.1161/01.cir.102.1.14
23. Halcox J, Deanfield J, Shamaei-Tousi A, Henderson B, Steptoe A, Coates ARM, et al. Circulating human heat shock protein 60 in the blood of healthy teenagers: a novel determinant of endothelial dysfunction and early vascular injur. Arterioscler Thromb Vasc Biol. 2005 Nov;25(11):e141-2. doi: http://dx.doi.org/10.1161/01.ATV.0000185832.34992.ff
24. Ranford JC, Henderson B. Chaperonins in disease: mechanisms, models, and treatments. Mol Pathol. 2002 Aug;55(4):209-13. doi: http://dx.doi.org/10.1136/mp.55.4.209
25. Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol. 2004;22:361-403. doi: http://dx.doi.org/10.1146/annurev.immunol.22.012703.104644
26. Mayr M, Metzler B, Kiechl S, Willeit J, Schett G, Xu Q, et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation. 1999 Mar;99(12):1560-6. doi: http://dx.doi.org/10.1161/01.cir.99.12.1560
27. Perschinka H, Mayr M, Millonig G, Mayerl C, van der Zee R, Morrison SG, et al. Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis. Arterioscler Thromb Vasc Biol. 2003 Jun;23(6):1060-5. doi: http://dx.doi.org/10.1161/01.ATV.0000071701.62486.49
28. Zhu J, Quyyumi AA, Rott D, Csako G, Wu H, Halcox J, et al. Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis. Circulation. 2001 Feb;103(8):1071-5. doi: http://dx.doi.org/10.1161/01.cir.103.8.1071
29. van Halm VP, Slot MC, Nurmohamed MT, Cohen Tervaert JW, Dijkmans BAC, et al. Antibodies against human 60 kDa heat shock protein are not associated with cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis. 2006 May;65(5):590-4. doi: http://dx.doi.org/10.1136/ard.2005.038828
30. Zou J, Rudwaleit M, Thiel A, Lauster R, Braun J, Sieper J. T cell response to human HSP60 and yersinia 19 kDa in ankylosing spondylitis and rheumatoid arthritis: no evidence for a causal role of these antigens in the pathogenesis. Ann Rheum Dis. 2002 May;61(5):473-4. doi: http://dx.doi.org/10.1136/ard.61.5.473
31. Steptoe A, Shamaei-Tousi A, Gylfe A, Bailey L, Bergström S, Coates A, et al. Protective effect of Human Heat Shock Protein 60 suggested by its association with decreased seropositivity to pathogens. Clin Vaccine Immunol. 2007 Feb;14(2):204-7. doi: http://dx.doi.org/10.1128/CVI.00179-06
32. Cohen-Sfady M, Nussbaum G, Pevsner-Fischer M, Mor F, Carmi P, Zanin-Zhorov A, et al. Heat shock protein 60 activates B cells via the TLR4-MyD88 pathway. J Immunol. 2005 Sep;175(6):3594-602. doi: http://dx.doi.org/10.4049/jimmunol.175.6.3594
33. Brar BK, Stephanou A, Wagstaff MJ, Coffin RS, Marber MS, Engelmann G, et al. Heat shock proteins delivered with a virus vector can protect cardiac cells against apoptosis as well as against thermal or ischaemic stress. J Mol Cell Cardiol. 1999 Jan;31(1):135-46. doi: http://dx.doi.org/10.1006/jmcc.1998.0857
34. Koch AE. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis. 2003 Nov;62(Suppl 2):ii60-7. doi: http://dx.doi.org/10.1136/ard.62.suppl_2.ii60
35. Zimmermann B, Lefèvre S, Fischer S, Gansler J, Lehr A, Rehart S, et al. Migratory potential and influence on neoangiogenesis of rheumatoid arthritis synovial fibroblasts. Ann Rheum Dis. 2010;69(Suppl 2):A57.
36. Rüger B, Giurea A, Wanivenhaus AH, Zehetgruber H, Hollemann D, Yanagida G, et al. Endothelial precursor cells in the synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 2004 Jul;50(7):2157-66. doi: http://dx.doi.org/10.1002/art.20506
37. Matsuno H, Yudoh K, Uzuki M, Nakazawa F, Sawai T, Yamaguchi N, et al. Treatment with the angiogenesis inhibitor endostatin: a novel therapy in rheumatoid arthritis. J Rheumatol. 2002 May;29(5):890-5.
38. Kahlon R, Shapero J, Gotlieb AI. Angiogenesis in atherosclerosis. Can J Cardiol. 1992 Jan-Feb;8(1):60-4.
39. George SJ. Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis. Curr Opin Lipidol. 1998 Oct;9(5):413-23. doi: http://dx.doi.org/10.1097/00041433-199810000-00005
40. Osterud B, Bjorklid E. Role of monocytes in atherogenesis. Physiol Rev. 2003 Oct;83(4):1069-112. doi: http://dx.doi.org/10.1152/physrev.00005.2003
41. Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, Kew RR, et al. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol. 1996 Feb;78(2):161-71. doi: http://dx.doi.org/10.1006/clin.1996.0025
42. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol. 2006 Jul;26(4):299-307. doi: http://dx.doi.org/10.1007/s10875-006-9022-6
43. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003 Jun;111(12):1805-12. doi: http://dx.doi.org/10.1172/JCI18921
44. Black S, Kushner I, Samols D. C-Reactive protein. J Biol Chem. 2004 Nov;279(47):48487-90. doi: http://dx.doi.org/10.1074/jbc.R400025200
45. Castell JV, Gómez-Lechón MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990 Nov;12(5):1179-86. doi: http://dx.doi.org/10.1002/hep.1840120517
46. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004 Mar;116 Suppl 6A:9S-16S. doi: http://dx.doi.org/10.1016/j.amjmed.2004.02.006
47. Pepys MB, Hirschfield GM. C-reactive protein and atherothrombosis. Ital Heart J. 2001 Mar;2(3):196-9.
48. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003 Dec;290(22):2945-51. doi: http://dx.doi.org/10.1001/jama.290.22.2945
49. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002 Nov;347(20):1557-65. doi: http://dx.doi.org/10.1056/NEJMoa021993
50. Blake GJ, Ridker PM. C-reactive protein: a surrogate risk marker or mediator of atherothrombosis. Am J Physiol Regul Integr Comp Physiol. 2003 Nov;285(5):R1250-2. doi: http://dx.doi.org/10.1152/ajpregu.00227.2003
51. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003 Jan;107(3):363-9. doi: http://dx.doi.org/10.1161/01.cir.0000053730.47739.3c
52. Jialal I, Devaraj S. Role of C-reactive protein in the assessment of cardiovascular risk. Am J Cardiol. 2003 Jan;91(2):200-2. doi: http://dx.doi.org/10.1016/s0002-9149(02)03110-7
53. Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, et al. Prognostic significance of the centers for disease control / American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation. 2007 Mar;115(12):1528-36. doi: http://dx.doi.org/10.1161/CIRCULATIONAHA.106.649939
54. Lemieux I, Pascot A, Prud'homme D, Alméras N, Bogaty P, Nadeau A, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol. 2001 Jun;21(6):961-7. doi: http://dx.doi.org/10.1161/01.atv.21.6.961
55. Miller M, Zhan M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2005 Oct;165(18):2063-8. doi: http://dx.doi.org/10.1001/archinte.165.18.2063
56. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000 Oct;102(18):2165-8. doi: http://dx.doi.org/10.1161/01.cir.102.18.2165
57. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001 Mar;158(3):1039-51. doi: http://dx.doi.org/10.1016/S0002-9440(10)64051-5
58. Penn MS, Topol EJ. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling. Circ Res. 2001 Jul;89(1):1-2. doi: http://dx.doi.org/10.1161/hh1301.093825
59. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation. 2001 Apr;103(13):1718-20. doi: http://dx.doi.org/10.1161/01.cir.103.13.1718
60. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation. 1996 Nov;94(9):2057-63. doi: http://dx.doi.org/10.1161/01.cir.94.9.2057
61. Cushman M, Lemaitre RN, Kuller LH, Psaty BM, Macy EM, Sharrett AR, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999 Mar;19(3):493-8. doi: http://dx.doi.org/10.1161/01.atv.19.3.493
62. Montero I, Orbe J, Varo N, Beloqui O, Monreal JI, Rodríguez J, et al. C-Reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells. doi: http://dx.doi.org/10.1016/j.jacc.2005.10.070
63. Masi AT, Aldag JC, Sipes J. Do elevated levels of serum C-reactive protein predict rheumatoid arthritis in men: correlations with pre-RA status and baseline positive rheumatoid factors. J Rheumatol. 2001 Oct;28(10):2359-61.
64. Nielen MMJ, van Schaardenburg D, Reesink HW, Twisk JWR, van de Stadt RJ, van der Horst-Bruinsma IE, et al. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum. 2004 Aug;50(8):2423-7. doi: http://dx.doi.org/10.1002/art.20431
65. Shadick NA, Cook NR, Karlson EW, Ridker PM, Maher NE, Manson JE, et al. C-reactive protein in the prediction of rheumatoid arthritis in women. Arch Intern Med. 2006 Dec;166(22):2490-4. doi: http://dx.doi.org/10.1001/archinte.166.22.2490
66. Pepys MB, Hawkins PN, Kahan MC, Tennent GA, Gallimore JR, Graham D, et al. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res. 2005 Nov;97(11):e97-103. doi: http://dx.doi.org/10.1161/01.RES.0000193595.03608.08
67. Liu C, Wang S, Deb A, Nath KA, Katusic ZS, McConnell JP, et al. Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial C-reactive protein on various human endothelial cell types in vitro: implications of contaminating presence of sodium azide in commercial preparation. Circ Res. 2005 Jul;97(2):135-43. doi: http://dx.doi.org/10.1161/01.RES.0000174612.90094.fd
68. Swafford AN, Bratz IN, Knudson JD, Rogers PA, Timmerman JM, Tune JD, et al. C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations. Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1786-95. doi: http://dx.doi.org/10.1152/ajpheart.00996.2004
69. Reifenberg K, Lehr H-A, Baskal D, Wiese E, Schaefer SC, Black S, et al. Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer. Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1641-6. doi: http://dx.doi.org/10.1161/01.ATV.0000171983.95612.90
70. Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 2005 Jun;102(23):8309-14. doi: http://dx.doi.org/10.1073/pnas.0503202102
71. Xia D, Samols D. Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. Proc Natl Acad Sci U S A. 1997 Mar;94(6):2575-80. doi: http://dx.doi.org/10.1073/pnas.94.6.2575
72. Mold C, Rodriguez W, Rodic-Polic B, Du Clos TW. C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R. J Immunol. 2002 Dec;169(12):7019-25. doi: http://dx.doi.org/10.4049/jimmunol.169.12.7019
73. Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2010 Feb;49(2):295-307. doi: http://dx.doi.org/10.1093/rheumatology/kep366
74. Huang Y, Salu K, Liu X, Li S, Wang L, Verbeken E, et al. Methotrexate loaded SAE coated coronary stents reduce neointimal hyperplasia in a porcine coronary model. Heart. 2004 Feb;90(2):195-9. doi: http://dx.doi.org/10.1136/hrt.2002.008169
75. Dixon WG, Symmons DPM. What effects might anti-TNF-alfa treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF-alfa in cardiovascular pathophysiology. Ann Rheum Dis. 2007 Sep;66(9):1132-6. doi: http://dx.doi.org/10.1136/ard.2006.063867
76. Hürlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, et al. Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 2002 Oct;106(17):2184-7. doi: http://dx.doi.org/10.1161/01.cir.0000037521.71373.44
77. Tikiz H, Arslan O, Pirildar T, Tikiz C, Bayindir P. The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis. Anadolu Kardiyol Derg. 2010 Apr;10(2):98-103. doi: http://dx.doi.org/10.5152/akd.2010.031
78. Galarraga B, Belch JJF, Pullar T, Ogston S, Khan F. Clinical improvement in rheumatoid arthritis is аssociated with healthier microvascular function in patients who respond to antirheumatic therapy. J Rheumatol. 2010 Mar;37(3):521-8. doi: http://dx.doi.org/10.3899/jrheum.090417
79. Yang X, Wan M, Cheng Z, Wang Z, Wu Q. Tofacitinib inhibits ox-LDL-induced adhesion of THP-1 monocytes to endothelial cells. Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2775-2782. doi: http://dx.doi.org/10.1080/21691401.2019.1573740
80. Boers M, Nurmohamed MT, Doelman CJA, Lard LR, Verhoeven AC, Voskuyl AE, et al. Influence of glucocorticoids and disease activity on total anf high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis. 2003 Sep;62(9):842-5. doi: http://dx.doi.org/10.1136/ard.62.9.842
81. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004 Jun;363(9426):2015-21. doi: http://dx.doi.org/10.1016/S0140-6736(04)16449-0
Information about authors:
Palhuyeva H.Y. – Candidate of Medical Sciences, associate professor of the Chair of Internal Medicine, Vitebsk State Order of Peoples’ Friendship Medical University;
Litvyakov A.M. – Doctor of Medical Sciences, professor, head of the Chair of Internal Medicine, Vitebsk State Order of Peoples’ Friendship Medical University.
Lagutchev V.V. – Candidate of Medical Sciences, associate professor of the Chair of Internal Medicine, Vitebsk State Order of Peoples’ Friendship Medical University.
Correspondence address: Republic of Belarus, 210009, Vitebsk, 27 Frunze ave, Vitebsk State Order of Peoples’ Friendship Medical University, Chair of Internal Medicine. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Hanna Y. Palhuyeva.
